دورية أكاديمية
The effects of silibin administration for different time periods on mouse liver with Ehrlich ascites carcinoma.
| العنوان: | The effects of silibin administration for different time periods on mouse liver with Ehrlich ascites carcinoma. |
|---|---|
| المؤلفون: | Beydogan AB; Department of Medical Biology, Faculty of Cerrahpasa Medicine, Istanbul University, Istanbul, Turkey., Bolkent S; Department of Medical Biology, Faculty of Cerrahpasa Medicine, Istanbul University, Istanbul, Turkey. Electronic address: semabolkent@yahoo.com. |
| المصدر: | Pharmacological reports : PR [Pharmacol Rep] 2016 Jun; Vol. 68 (3), pp. 543-9. Date of Electronic Publication: 2015 Dec 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101234999 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2299-5684 (Electronic) Linking ISSN: 17341140 NLM ISO Abbreviation: Pharmacol Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : Cham, Switzerland : Springer International Publishing Original Publication: Kraków, Poland : Institute of Pharmacology, Polish Academy of Sciences, c2005- |
| مواضيع طبية MeSH: | Carcinoma, Ehrlich Tumor/*drug therapy , Liver/*drug effects , Silymarin/*pharmacology , Silymarin/*therapeutic use, Animals ; Apoptosis/drug effects ; Autoantibodies/metabolism ; Carcinoma, Ehrlich Tumor/metabolism ; Carcinoma, Ehrlich Tumor/pathology ; Caspases/metabolism ; Drug Administration Schedule ; Liver/metabolism ; Liver/pathology ; Male ; Malondialdehyde/metabolism ; Matrix Metalloproteinases/metabolism ; Mice ; Proliferating Cell Nuclear Antigen/immunology ; Silybin ; Superoxide Dismutase/metabolism |
| مستخلص: | Background: Ehrlich ascites carcinoma is the one of the animal cancer models having high malignancy and rapid growth resistance. Silibin has reported to be an antioxidant in previous studies. We aimed to investigate the effects of silibin on mouse liver with Ehrlich ascites tumor (EAT) cells in different time periods. Methods: Balb/c mice were divided into five groups. Group I (Control): The saline buffer (sb) was injected intraperitoneally (ip) to the mice for 15 days. Group II (Silibin): 150mg/kg silibin was injected ip for 15 days. Group III (Ehrlich): 2×10(5) cells were transferred from the donor mouse to healthy mice on first day. Group IV (Ehrlich+Silibin): Silibin was given between 5th and 15th days to mice inoculated with EAT. Group V (Silibin+Ehrlich): Silibin was injected for 15 days after EAT cells. The liver sections were stained with matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9), caspase 3, caspase 8, and proliferating cell nuclear antigen (PCNA) antibodies by the streptavidin-biotin-peroxidase technique. Biochemical analysis and Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) method were performed in the liver. Results: Superoxide dismutase levels of liver increased in Ehrlich+Silibin group compared with Ehrlich group. Malondialdehyde levels significantly decreased in Silibin+Ehrlich group compared with Ehrlich+Silibin. MMP-2 and MMP-9 immunopositive cells increased in Silibin+Ehrlich compared with Ehrlich group. Caspase 3 and TUNEL signals significantly increased in Silibin+Ehrlich group compared with Ehrlich group. PCNA positive signals significantly increased in Ehrlich+Silibin group compared with Ehrlich group. Conclusion: According to our findings, we suggest that silibin treatment after EAT cells inoculation has more effective than concurrently EAT and silibin treatment. (Copyright © 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Antioxidant; Ehrlich ascites tumor (EAT); Mouse; Silibin |
| المشرفين على المادة: | 0 (Autoantibodies) 0 (Proliferating Cell Nuclear Antigen) 0 (Silymarin) 4RKY41TBTF (Silybin) 4Y8F71G49Q (Malondialdehyde) EC 1.15.1.1 (Superoxide Dismutase) EC 3.4.22.- (Caspases) EC 3.4.24.- (Matrix Metalloproteinases) |
| تواريخ الأحداث: | Date Created: 20160219 Date Completed: 20170627 Latest Revision: 20200106 |
| رمز التحديث: | 20240513 |
| DOI: | 10.1016/j.pharep.2015.12.003 |
| PMID: | 26891241 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2299-5684 |
|---|---|
| DOI: | 10.1016/j.pharep.2015.12.003 |